Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy
Barry J. Maron, MD, FACC*,*,
J.G. Seidman, PhD*, and
Christine E. Seidman, MD*,
* Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota
Department of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts

View larger version (88K):
[in a new window]
|
Figure 1 Late-onset left ventricular (LV) hypertrophy confined to the apical region, documented by serial echocardiography in a 60-year-old woman with familial hypertrophic cardiomyopathy (HCM) due to a myosin-binding protein C mutation. The patient has remained free of HCM-related cardiac symptoms. (A) Apical four-chamber cross-sectional view obtained at 55 years of age as part of a cardiac evaluation unrelated to HCM, showing the absence of LV hypertrophy with apical endocardium delineated by the broken line. (B) Similar echocardiographic cross-sectional plane, five years later, showing marked segmental hypertrophy confined to the LV apex (asterisk and broken line), which has developed over that period of time. LA = left atrium; MV = mitral valve; RA = right atrium; RV = right ventricle.
|
|
|